{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:07:33Z","timestamp":1787026053470,"version":"build-2736575974"},"reference-count":50,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Circ Biomark"],"abstract":"<jats:p>Introduction: Hepatocellular carcinoma (HCC) is a global health challenge, with disproportionately high mortalityrates in low- and middle-income countries (LMICs). Tumor markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) are used for diagnostic purposes and for monitoring treatment results. The relationship between these markers, individually or in combination, with clinicalpresentation, metastatic patterns and survival outcomes has not been extensively researched.Methods: In this South African retrospective study, we assess the association of the tumor marker levels on presentation, diagnosis, and prognosis. Data was analyzed using chi-square tests, t-tests, and Kaplan-Meier survivalanalysis.Results: The study included 501 patients, treated between 2010 and 2024. Elevated AFP levels were associatedwith chronic hepatitis B virus (HBV) infection, hepatomegaly, and pulmonary metastases, while elevated CA19-9levels were associated with more advanced liver disease. Survival analysis confirmed shorter survival for patientswith elevated AFP and CA19-9 levels compared to normal levels (p &lt; 0.001). Elevated CEA levels were not significantlyassociated with survival. Patients with no elevated markers (i.e., \u201ctriple-negative\u201d for AFP, CEA, and CA19-9) had the longest survival, compared to those with multiple elevated markers (p &lt; 0.001).Conclusion: AFP and CA19-9 elevations were associated with more advanced disease and poorer survival outcomes.We emphasize the importance of integrating tumor marker levels with imaging and histopathology for amultimodal diagnostic approach. Further research is needed to validate these associations to better define therole of biomarkers in HCC management.<\/jats:p>","DOI":"10.33393\/jcb.2026.3637","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:52:04Z","timestamp":1769763124000},"page":"8-14","source":"Crossref","is-referenced-by-count":1,"title":["Secretory versus non-secretory hepatocellular carcinoma: associations of serum AFP, CEA and CA19-9 levels with clinical presentation, metastatic patterns, and survival"],"prefix":"10.33393","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2148-685X","authenticated-orcid":false,"given":"Muhammad","family":"Emmamally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1405-474X","authenticated-orcid":false,"given":"Urda","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9638-5314","authenticated-orcid":false,"given":"Rufaida","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4456-2115","authenticated-orcid":false,"given":"Sanju","family":"Sobnach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-9156","authenticated-orcid":false,"given":"Jake","family":"Krige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-301X","authenticated-orcid":false,"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-8329","authenticated-orcid":false,"given":"Mark","family":"Sonderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-256X","authenticated-orcid":false,"given":"Eduard","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"18739","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https:\/\/doi.org\/10.3322\/caac.21660 PMID:33538338","DOI":"10.3322\/caac.21660"},{"key":"18740","doi-asserted-by":"crossref","unstructured":"Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598-1606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021 PMID:36208844","DOI":"10.1016\/j.jhep.2022.08.021"},{"key":"18741","doi-asserted-by":"crossref","unstructured":"Jonas E, Bernon M, Robertson B, et al.; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. Lancet Gastroenterol Hepatol. 2022;7(11):1049-1060. https:\/\/doi.org\/10.1016\/S2468-1253(22)00042-5 PMID:35810767","DOI":"10.1016\/S2468-1253(22)00042-5"},{"key":"18742","unstructured":"London WT, McGlynn K, Schottenfeld D, et al. Cancer epidemiology and prevention. Cancer Epidemiology and Prevention Schottenfeld D and Fraumeni Jr JF (eds) 3rd edition Oxford University Press, New York, NY, pp. 763-786. 2006. https:\/\/books.google.com\/books?hl=en&lr=&id=qfN8Y1_lbDYC&oi=fnd&pg=PR9&dq=London+WT,+McGlynn+K,+Schottenfeld+D,+et+al.+Cancer+epide-+miology+and+prevention.+Cancer+Epidemiology+and+Prevention+Schottenfeld+D+and+Fraumeni+Jr+JF+(eds)+3rd+edition+Oxford+University+Press,+New+York,+NY,+pp.+763-786.+2006.+&ots=DilEnw0NE0&sig=hN0-CWEOjGVu-WjIV90vlvvtQBg"},{"key":"18743","doi-asserted-by":"crossref","unstructured":"Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609-e616. https:\/\/doi.org\/10.1016\/S2214-109X(16)30143-7 PMID:27470177","DOI":"10.1016\/S2214-109X(16)30143-7"},{"key":"18744","doi-asserted-by":"crossref","unstructured":"Yang JD, Mohamed EA, Aziz AOA, et al.; Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2(2):103-111. https:\/\/doi.org\/10.1016\/S2468-1253(16)30161-3 PMID:28403980","DOI":"10.1016\/S2468-1253(16)30161-3"},{"key":"18745","doi-asserted-by":"crossref","unstructured":"Ndow G, Vo-Quang E, Shimakawa Y, et al. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, West Africa: a prospective cohort study. Lancet Glob Health. 2023;11(9):e1383-e1392. https:\/\/doi.org\/10.1016\/S2214-109X(23)00263-2 PMID:37517420","DOI":"10.1016\/S2214-109X(23)00263-2"},{"key":"18746","doi-asserted-by":"crossref","unstructured":"Vitale A, Svegliati-Baroni G, Ortolani A, et al.; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut. 2023;72(1):141-152. https:\/\/doi.org\/10.1136\/gutjnl-2021-324915 PMID:34933916","DOI":"10.1136\/gutjnl-2021-324915"},{"key":"18747","doi-asserted-by":"crossref","unstructured":"Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9 PMID:28620797","DOI":"10.1007\/s12072-017-9799-9"},{"key":"18748","doi-asserted-by":"crossref","unstructured":"Kudo M, Matsui O, Izumi N, et al.; Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3(3-4):458-468. https:\/\/doi.org\/10.1159\/000343875 PMID:26280007","DOI":"10.1159\/000343875"},{"key":"18749","doi-asserted-by":"crossref","unstructured":"Bruix J, Sherman M.; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-1022. https:\/\/doi.org\/10.1002\/hep.24199 PMID:21374666","DOI":"10.1002\/hep.24199"},{"key":"18750","doi-asserted-by":"crossref","unstructured":"Wald C, Russo MW, Heimbach JK, et al. New OPTN\/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiological Society of North America, Inc. 2013:376-382.","DOI":"10.1148\/radiol.12121698"},{"key":"18751","doi-asserted-by":"crossref","unstructured":"Benson AB III, D\u2019Angelica MI, Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw. 2017;15(5):563-573. https:\/\/doi.org\/10.6004\/jnccn.2017.0059 PMID:28476736","DOI":"10.6004\/jnccn.2017.0059"},{"key":"18752","doi-asserted-by":"crossref","unstructured":"Yeh YP, Hu TH, Cho PY, et al.; Changhua Community-Based Abdominal Ultrasonography Screening Group. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology. 2014;59(5):1840-1849. https:\/\/doi.org\/10.1002\/hep.26703 PMID:24002724","DOI":"10.1002\/hep.26703"},{"key":"18753","doi-asserted-by":"crossref","unstructured":"Qin C, Gao Y, Li J, et al. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett. 2021;21(6):487. https:\/\/doi.org\/10.3892\/ol.2021.12748 PMID:33968203","DOI":"10.3892\/ol.2021.12748"},{"key":"18754","doi-asserted-by":"crossref","unstructured":"Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214-2229. https:\/\/doi.org\/10.1111\/liv.14223 PMID:31436873","DOI":"10.1111\/liv.14223"},{"key":"18755","unstructured":"Edoo MIA, Chutturghoon VK, Wusu-Ansah GK, et al. Serum biomarkers AFP, CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma. Iran J Public Health. 2019;48(2):314-322. PMID:31205886"},{"key":"18756","doi-asserted-by":"crossref","unstructured":"Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(10):2439-2446. https:\/\/doi.org\/10.1007\/s00432-020-03331-6 PMID:32725355","DOI":"10.1007\/s00432-020-03331-6"},{"key":"18757","doi-asserted-by":"crossref","unstructured":"Bai DS, Zhang C, Chen P, et al. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. https:\/\/doi.org\/10.1038\/s41598-017-12834-1 PMID:28993684","DOI":"10.1038\/s41598-017-12834-1"},{"key":"18758","unstructured":"Gitlin D, Perricelli A, Gitlin GM. Synthesis of \u2013fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res. 1972;32(5):979-982. PMID:4111729"},{"key":"18759","unstructured":"Yachnin S. The clinical significance of human alpha-fetoprotein. Ann Clin Lab Sci. 1978;8(2):84-90. PMID:76458"},{"key":"18760","doi-asserted-by":"crossref","unstructured":"Masseyeff R, Gilli J, Krebs B, et al. Evolution of alpha-fetoprotein serum levels throughout life in humans and rats, and during pregnancy in the rat. Ann N Y Acad Sci. 1975;259(1):17-28. https:\/\/doi.org\/10.1111\/j.1749-6632.1975.tb25398.x PMID:54020","DOI":"10.1111\/j.1749-6632.1975.tb25398.x"},{"key":"18761","doi-asserted-by":"crossref","unstructured":"Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci. 1992;303(3):157-159. https:\/\/doi.org\/10.1097\/00000441-199203000-00004 PMID:1375809","DOI":"10.1097\/00000441-199203000-00004"},{"key":"18762","doi-asserted-by":"crossref","unstructured":"Sauzay C, Petit A, Bourgeois AM, et al. Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39-44. https:\/\/doi.org\/10.1016\/j.cca.2016.10.006 PMID:27732875","DOI":"10.1016\/j.cca.2016.10.006"},{"key":"18763","doi-asserted-by":"crossref","unstructured":"Wang X, Wang Q. Alpha\u2010fetoprotein and hepatocellular carcinoma immunity. Can J Gastroenterol Hepatol. 2018;2018(1):9049252. PMID:29805966","DOI":"10.1155\/2018\/9049252"},{"key":"18764","doi-asserted-by":"crossref","unstructured":"Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26(2):599-603. https:\/\/doi.org\/10.1007\/s12253-019-00585-5 PMID:30661224","DOI":"10.1007\/s12253-019-00585-5"},{"key":"18765","doi-asserted-by":"crossref","unstructured":"Yu Z, Chen D, Zheng Y, et al. Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(13):11295-11308. https:\/\/doi.org\/10.1007\/s00432-023-04997-4 PMID:37368120","DOI":"10.1007\/s00432-023-04997-4"},{"key":"18766","doi-asserted-by":"crossref","unstructured":"Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138-143. https:\/\/doi.org\/10.1016\/j.lungcan.2011.11.012 PMID:22153832","DOI":"10.1016\/j.lungcan.2011.11.012"},{"key":"18767","doi-asserted-by":"crossref","unstructured":"Sarobe P, Huarte E, Lasarte JJ, et al. Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr Cancer Drug Targets. 2004;4(5):443-454. https:\/\/doi.org\/10.2174\/1568009043332916 PMID:15320719","DOI":"10.2174\/1568009043332916"},{"key":"18768","doi-asserted-by":"crossref","unstructured":"Macnab GM, Urbanowicz JM, Kew MC. Carcinoembryonic antigen in hepatocellular cancer. Br J Cancer. 1978;38(1):51-54. https:\/\/doi.org\/10.1038\/bjc.1978.162 PMID:80223","DOI":"10.1038\/bjc.1978.162"},{"key":"18769","doi-asserted-by":"crossref","unstructured":"Verma N, Vinocha A. Role of CA 19.9 and CEA in predicting diagnosis in hepatocellular carcinoma. J Cancer Res Ther. 2023;19(5):1356-1358. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1280_21 PMID:37787308","DOI":"10.4103\/jcrt.jcrt_1280_21"},{"key":"18770","doi-asserted-by":"crossref","unstructured":"Scar\u00e0 S, Bottoni P, Scatena R. CA 19-9: Biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247-60. https:\/\/doi.org\/10.1007\/978-94-017-7215-0_15 PMID: 26530370.","DOI":"10.1007\/978-94-017-7215-0_15"},{"key":"18771","doi-asserted-by":"crossref","unstructured":"Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018;18(8):862-867. https:\/\/doi.org\/10.1016\/j.pan.2018.09.004 PMID:30249386","DOI":"10.1016\/j.pan.2018.09.004"},{"key":"18772","doi-asserted-by":"crossref","unstructured":"Katz A, Hanlon A, Lanciano R, et al. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(2):393-396. https:\/\/doi.org\/10.1016\/S0360-3016(97)85626-X PMID:9607356","DOI":"10.1016\/S0360-3016(98)00058-3"},{"key":"18773","doi-asserted-by":"crossref","unstructured":"Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit. 2015;21:3555-3563. https:\/\/doi.org\/10.12659\/MSM.895040 PMID:26576628","DOI":"10.12659\/MSM.895040"},{"key":"18774","doi-asserted-by":"crossref","unstructured":"Maussier ML, Valenza V, Schinco G, et al. AFP, CEA, CA 19-9 and TPA in hepatocellular carcinoma. Int J Biol Markers. 1990;5(3):121-126. https:\/\/doi.org\/10.1177\/172460089000500304 PMID:1704905","DOI":"10.1177\/172460089000500304"},{"key":"18775","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, et al.; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208 PMID:31078660","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"18776","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010 PMID:18929686","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"18777","doi-asserted-by":"crossref","unstructured":"Kim KM, Shim SG, Sinn DH, et al. Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites? Scand J Gastroenterol. 2020;55(8):951-957. https:\/\/doi.org\/10.1080\/00365521.2020.1788139 PMID:32698637","DOI":"10.1080\/00365521.2020.1788139"},{"key":"18778","unstructured":"IBM. SPSS Armonk, NY2019. https:\/\/www.ibm.com\/products\/spss-statistics"},{"key":"18779","doi-asserted-by":"crossref","unstructured":"Yeo YH, Lee YT, Tseng HR, et al. Alpha-fetoprotein: past, present, and future. Hepatol Commun. 2024;8(5):e0422. https:\/\/doi.org\/10.1097\/HC9.0000000000000422 PMID:38619448","DOI":"10.1097\/HC9.0000000000000422"},{"key":"18780","doi-asserted-by":"crossref","unstructured":"Zhang J, Chen G, Zhang P, et al. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2020;15(2):e0228857. https:\/\/doi.org\/10.1371\/journal.pone.0228857 PMID:32053643","DOI":"10.1371\/journal.pone.0228857"},{"key":"18781","doi-asserted-by":"crossref","unstructured":"Wu ZY, Li H, Chen JL, et al. Nomogram model based on \u03b3-glutamyl transferase to albumin ratio predicts survival in hepatocellular carcinoma patients with transarterial chemoembolization treatment. World J Gastrointest Oncol. 2024;16(12):4650-4662. https:\/\/doi.org\/10.4251\/wjgo.v16.i12.4650 PMID:39678787","DOI":"10.4251\/wjgo.v16.i12.4650"},{"key":"18782","unstructured":"Corti A, Franzini M, Paolicchi A, et al. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30(4):1169-1181. PMID:20530424"},{"key":"18783","doi-asserted-by":"crossref","unstructured":"Hanigan MH, Gallagher BC, Townsend DM, et al. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis. 1999;20(4):553-559. https:\/\/doi.org\/10.1093\/carcin\/20.4.553 PMID:10223181","DOI":"10.1093\/carcin\/20.4.553"},{"key":"18784","doi-asserted-by":"crossref","unstructured":"Brechot C, Kremsdorf D, Soussan P, et al. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol (Paris). 2010;58(4):278-287. https:\/\/doi.org\/10.1016\/j.patbio.2010.05.001 PMID:20667665","DOI":"10.1016\/j.patbio.2010.05.001"},{"key":"18785","doi-asserted-by":"crossref","unstructured":"Yu M, Huang L, Zhang S, et al. Follow-up value of serum AFP and aminotransferases in chronic hepatitis B progression. Front Cell Infect Microbiol. 2023;13:1082390. https:\/\/doi.org\/10.3389\/fcimb.2023.1082390 PMID:36761898","DOI":"10.3389\/fcimb.2023.1082390"},{"key":"18786","doi-asserted-by":"crossref","unstructured":"Lee HJ, Yeon JE, Suh SJ, et al. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8(2):177-185. https:\/\/doi.org\/10.5009\/gnl.2014.8.2.177 PMID:24672660","DOI":"10.5009\/gnl.2014.8.2.177"},{"key":"18787","doi-asserted-by":"crossref","unstructured":"Yu MC, Lee YS, Lin SE, et al. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19(S3)(suppl 3):S455-S463. https:\/\/doi.org\/10.1245\/s10434-011-1946-2 PMID:21822558","DOI":"10.1245\/s10434-011-1946-2"},{"key":"18788","doi-asserted-by":"crossref","unstructured":"Zhou F, Shang W, Yu X, et al. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38(2):741-767. https:\/\/doi.org\/10.1002\/med.21455 PMID:28621802","DOI":"10.1002\/med.21455"}],"container-title":["Journal of Circulating Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3637\/4205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3637\/4206","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3637\/4199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3637\/4205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:52:11Z","timestamp":1769763131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/view\/3637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,26]]}},"URL":"https:\/\/doi.org\/10.33393\/jcb.2026.3637","relation":{},"ISSN":["1849-4544","1849-4544"],"issn-type":[{"value":"1849-4544","type":"electronic"},{"value":"1849-4544","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}